Actualités AIDA Pharmaceuticals Inc (CE) - AIDA | Actions OTCMarkets

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

- Amended Termination of Registration of a Class of Security under Section 12(g) (15-12G/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 15 CERTIFICATION AND NOTICE OF TERMINATION...

- Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) S...

- Notification that Quarterly Report will be submitted late (NT 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one...

Aida Pharmaceuticals Inc - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One...

Aida Pharmaceuticals Inc - Amended Current report filing (8-K/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13...

Aida Pharmaceuticals Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one) £ ...

Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing

SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that the...

Aida Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the...

Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition

SANTA MONICA, Calif., April 24 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that it...

Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website

SANTA MONICA, Calif., April 22 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced the...

Aida Announces New Anti-Cancer Drug Under Development

SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) (hereinafter referred to...

Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development

SANTA MONICA, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today announced that...

Aida Pharmaceuticals Inc - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the...

Aida Pharmaceuticals, Inc. Releases Fiscal 2007 Annual Report on Form 10-KSB

Report Shows 88% Increase in Net Income and Doubling of Net Margins SANTA MONICA, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Aida...

Aida Pharmaceuticals Inc - Annual Report (Small Business Issuers) (10KSB)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) £...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AIDA Pharmaceuticals Inc (CE) (AIDA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

AIDA Actualités

- Amended Termination of Registration of a Class of Security under Section 12(g) (15-12G/A)

- Quarterly Report (10-Q)

- Notification that Quarterly Report will be submitted late (NT 10-Q)

Aida Pharmaceuticals Inc - Quarterly Report (10-Q)

Aida Pharmaceuticals Inc - Amended Current report filing (8-K/A)

Aida Pharmaceuticals Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)

Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing

Aida Pharmaceuticals Inc - Current report filing (8-K)

Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition

Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website

Aida Announces New Anti-Cancer Drug Under Development

Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development

Aida Pharmaceuticals Inc - Current report filing (8-K)

Aida Pharmaceuticals, Inc. Releases Fiscal 2007 Annual Report on Form 10-KSB

Aida Pharmaceuticals Inc - Annual Report (Small Business Issuers) (10KSB)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

AIDA Pharmaceuticals Inc (CE) (AIDA) Actualités

AIDA Pharmaceuticals Inc (CE) (AIDA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

AIDA Actualités

- Amended Termination of Registration of a Class of Security under Section 12(g) (15-12G/A)

- Quarterly Report (10-Q)

- Notification that Quarterly Report will be submitted late (NT 10-Q)

Aida Pharmaceuticals Inc - Quarterly Report (10-Q)

Aida Pharmaceuticals Inc - Amended Current report filing (8-K/A)

Aida Pharmaceuticals Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)

Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing

Aida Pharmaceuticals Inc - Current report filing (8-K)

Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition

Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website

Aida Announces New Anti-Cancer Drug Under Development

Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development

Aida Pharmaceuticals Inc - Current report filing (8-K)

Aida Pharmaceuticals, Inc. Releases Fiscal 2007 Annual Report on Form 10-KSB

Aida Pharmaceuticals Inc - Annual Report (Small Business Issuers) (10KSB)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application